Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
Add more filters










Publication year range
1.
Vet Parasitol ; 249: 21-29, 2018 Jan 15.
Article in English | MEDLINE | ID: mdl-29279083

ABSTRACT

Soluble parasite antigens (SPA) in supernatants of in vitro cultures of Babesia canis can be used to vaccinate dogs against virulent B. canis infection. The moment that immunity becomes apparent coincides with the appearance of antibodies against SPA in the serum of the vaccinated animals. This so-called vaccination-challenge serum (VC-serum) was used to precipitate antigens from B. canis culture supernatants in agarose gels. This antigen preparation was then used to analyse the reactivity of sera from vaccinated dogs on western blots. RESULTS: showed that the first appearance of antibody reactivity against a protein that migrated at the 39kDa position in SDS-PAGE gels was associated with the moment vaccinated dogs started to recover from a virulent challenge infection. In addition, pulse-chase experiments revealed that a 39-40kDa doublet was released into the supernatant of B. canis cultures starting 15min after the chase. This doublet was specifically precipitated by VC-serum, thus corroborating that the 39-40kDa doublet in SPA preparations was of parasite origin. Partial amino acid sequencing allowed the discovery of the gene that encoded the 39-40kDa doublet (canine Babesia antigen; CBA). The full-length gene was cloned and expressed in E. coli. The recombinant CBA protein (rCBA) was recognized by VC-serum, and antibodies against rCBA precipitated the 39kDa antigen of SPA preparations and of merozoites of B. canis. In addition, anti-rCBA serum reacted with the surface of B. canis merozoites (but not with B. rossi merozoites) in immunofluorescence. Vaccination of dogs with rCBA induced antibodies against rCBA, which recognized B. canis merozoites. Vaccinated dogs were protected against virulent challenge infection by limiting parasite proliferation. As a result, the development of clinical signs was prevented and the animals self-cured. In contrast, six out of seven non-vaccinated control dogs developed relatively high parasitaemia and serious clinical signs associated with poor tissue perfusion. This antigen can be used to replace the SPA antigen in the conventional B. canis vaccines, which eliminates the need for dog blood and serum for vaccine production.


Subject(s)
Antigens, Protozoan/genetics , Antigens, Protozoan/immunology , Babesiosis/immunology , Dog Diseases/immunology , Protozoan Vaccines/genetics , Protozoan Vaccines/immunology , Recombinant Proteins/immunology , Animals , Antibodies, Protozoan/blood , Babesia/genetics , Babesia/immunology , Babesiosis/parasitology , Babesiosis/prevention & control , Dog Diseases/parasitology , Dog Diseases/prevention & control , Dogs
2.
J S Afr Vet Assoc ; 80(2): 75-8, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19831266

ABSTRACT

Babesia canis and B. rossi are large Babesia species that infect dogs and cause clinical disease. The spectrum of disease is highly diverse with either parasite, but upon evaluation of field cases it has been suggested that in general B. rossi is more virulent than B. canis. This difference was also found in experimental infections using B. canis and B. rossi isolates and appeared to be related to a difference in parasitaemia. Whether this difference reflects the essential difference between B. canis and B. rossi species in general, or merely reflects the variability in virulence of individual isolates cannot be discerned. Comparative in vitro and in vivo studies revealed a number of qualitative differences between the B. canis and B. rossi isolates studied; however, more research is required to determine any causal relationship between in vitro and in vivo characteristics. Vaccination with a bivalent vaccine (containing soluble parasite antigen [SPA] from supernatants of in vitro cultures of B. canis and B. rossi) induced protection against clinical babesiosis upon challenge infection with either parasite. The dynamics of parasitaemia upon challenge infection of vaccinated animals indicated a biological difference between the B. canis and B. rossi isolates studied. Vaccinated dogs that were challenged with B. rossi parasites (2 isolates tested) effectively controlled parasitaemia. By contrast, in vaccinated dogs that were challenged with B. canis isolates (2 isolates tested) there was little or no effect on parasitaemia but levels of SPA in plasma were reduced. Apparently the nature of vaccine-induced immunity differs with respect to the challenge species.


Subject(s)
Antigens, Protozoan/immunology , Babesia/immunology , Babesiosis/veterinary , Dog Diseases/parasitology , Protozoan Vaccines/immunology , Animals , Babesia/classification , Babesia/pathogenicity , Babesiosis/parasitology , Babesiosis/prevention & control , Dog Diseases/prevention & control , Dogs , Protozoan Vaccines/administration & dosage , Vaccination/veterinary , Virulence
3.
Vet Parasitol ; 138(1-2): 140-6, 2006 May 31.
Article in English | MEDLINE | ID: mdl-16504401

ABSTRACT

It has previously been shown that dogs can be vaccinated against heterologous Babesia canis infection using a vaccine containing soluble parasite antigens (SPA) from in vitro cultures of B. canis and B. rossi that are adjuvanted with saponin. In the present study the onset and duration of immunity of vaccinated dogs were studied. Results showed that 3-26 weeks after initial vaccination, dogs effectively limit the level of SPA in plasma upon challenge infection, which was reflected in limited duration and extent of clinical manifestations. There was no statistically significant effect of vaccination on the parasite load in the circulation, which was determined from blood smears. It was further shown that the level of immunity of primary vaccinated dogs (priming and booster vaccination with a 6-week interval) and that of repeatedly vaccinated dogs (a single additional vaccination 6 months after primary vaccination) is comparable. From this study it is concluded that vaccination with this preparation induces protective immunity against clinical babesiosis from 3 weeks after booster vaccination onwards, and remains effective for a period of at least another 6 months. A single booster vaccination is sufficient to maintain immunity for at least another 6 months.


Subject(s)
Antigens, Protozoan/immunology , Babesia/immunology , Babesiosis/veterinary , Dog Diseases/immunology , Dog Diseases/prevention & control , Protozoan Vaccines/immunology , Analysis of Variance , Anemia/etiology , Anemia/veterinary , Animals , Antigens, Protozoan/administration & dosage , Antigens, Protozoan/blood , Babesiosis/complications , Babesiosis/immunology , Babesiosis/prevention & control , Dog Diseases/parasitology , Dogs , Female , Hematocrit/veterinary , Male , Parasitemia/veterinary , Protozoan Vaccines/administration & dosage , Protozoan Vaccines/standards , Statistics as Topic
4.
Infect Immun ; 71(3): 1056-67, 2003 Mar.
Article in English | MEDLINE | ID: mdl-12595415

ABSTRACT

As part of a search for homologous members of the Plasmodium falciparum Pf60 multigene family in the intraerythrocytic protozoan parasite Babesia canis, we report here the characterization of a cDNA of 1,115 bp, which was designated Bcvir for its potential viral origin. The Bcvir cDNA contained two overlapping open reading frames (ORFs) (ORF1 from nucleotide [nt] 61 to 486 and ORF2 from nt 417 to 919), where Bcvir15, the deduced ORF1 peptide (M(1) to I(141)), is the main expressed product. The Bcvir cDNA was derived from an extrachromosomal dsRNA element of 1.2 kbp that was always found associated with a double-stranded RNA (dsRNA) of 2.8 kbp by hybridization, and no copy of this cDNA sequence was found in B. canis genomic DNA. Biochemical characterization of Bcvir15, by using polyclonal rabbit sera directed against recombinant proteins, indicated that it is a soluble protein which remained associated with the cytoplasm of the B. canis merozoite. Interestingly, purified immunoglobulins from the anti-glutathione S-transferase-Bcvir15 (at a concentration of 160 micro g/ml) induced 50% inhibition of the in vitro growth of B. canis, and the inhibitory effect was associated with morphological damage of the parasite. Our data suggest that the extrachromosomal dsRNA-encoded Bcvir15 protein might interfere with the intracellular growth of the parasite rather than with the process of invasion of the host cell by the merozoite. Epitope mapping of Bcvir15 identified three epitopes that might be essential for the function of the protein.


Subject(s)
Antibodies, Protozoan/immunology , Babesia/immunology , Protozoan Proteins/immunology , RNA, Double-Stranded/genetics , Amino Acid Sequence , Animals , Babesia/genetics , Babesia/growth & development , DNA, Complementary/chemistry , DNA, Complementary/isolation & purification , Epitope Mapping , Molecular Sequence Data , Protozoan Proteins/chemistry , Protozoan Proteins/genetics , Rabbits
5.
Vet Parasitol ; 100(1-2): 75-86, 2001 Sep 12.
Article in English | MEDLINE | ID: mdl-11522408

ABSTRACT

Soluble parasite antigens (SPA) from European Babesia canis can be used to protect dogs against a homologous but not heterologous challenge infection. In this study it is shown that when dogs are vaccinated with a mixture of SPA from both, a European B. canis isolate and a South African Babesia rossi isolate, protective immunity against heterologous B. canis infection is induced. Three groups of five beagle dogs each were vaccinated twice with graded doses of SPA derived from in vitro cultures of B. canis and B. rossi, with a 3-week interval. Saponin was used as adjuvant. Three weeks after booster vaccination immunological responsiveness against heterologous B. canis antigen was measured by seroconversion against infected erythrocytes and lymphocyte transformation using SPA. Upon vaccination dogs produced antibodies against infected erythrocytes and lymphoblastogenic responses against SPA in a dose-dependent manner. Dogs were then challenged with heterologous B. canis parasites. Dogs appeared to be protected against challenge infection, which was reflected in less severe decrease of packed cell volume (PCV) and reduced clinical signs. The level of protection to clinical signs (but not excessive PCV drop) was related to the level of SPA in plasma and spleen size, and not related to peripheral parasitaemia. The results suggest that vaccination with this bivalent vaccine primes T-helper cells that recognise common epitopes on SPA from an antigenically distinct B. canis isolate. These cells provide the essential Th signal to mount an effective and timely antibody response against SPA and parasites or parasitised erythrocytes, which prevents the further development of clinical babesiosis.


Subject(s)
Antigens, Protozoan/immunology , Babesia/immunology , Babesiosis/veterinary , Dog Diseases/prevention & control , Protozoan Vaccines/immunology , Animals , Antibodies, Protozoan/biosynthesis , Babesiosis/immunology , Babesiosis/prevention & control , Dog Diseases/immunology , Dog Diseases/parasitology , Dogs , Dose-Response Relationship, Immunologic , Erythrocytes/immunology , Erythrocytes/parasitology , Hematocrit/veterinary , Immunization, Secondary , Lymphocyte Activation/immunology , Male , Parasitemia/immunology , Parasitemia/veterinary
6.
Eur J Biochem ; 265(3): 1015-21, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10518797

ABSTRACT

In the search for immunoprotective antigens of the intraerythrocytic Babesia canis rossi parasite, a new cDNA was cloned and sequenced. Protein sequence database searches suggested that the 41-kDa protein belongs to the phosphofructokinase B type family (PFK-B). However, because of the low level sequence identity (< 20%) of the protein both with adenosine and sugar kinases from this family, its structural and functional features were further investigated using molecular modelling and enzymatic assays. The sequence/structure comparison of the protein with the crystal structure of a member of the PFK-B family, Escherichia coli ribokinase (EcRK), suggested that it might also form a stable and active dimer and revealed conservation of the ATP-binding site. However, residues specifically involved in the ribose-binding sites in the EcRK sequence (S and N) were substituted in its sequence (by H and M, respectively), and were suspected of binding adenosine compounds rather than sugar ones. Enzymatic assays using a purified glutathione S-transferase fusion protein revealed that this protein exhibits rapid catalysis of the phosphorylation of adenosine with an apparent Km value of 70 nM, whereas it was inactive on ribose or other carbohydrates. As enzymatic assays confirmed the results of the structure/function analysis indicating a preferential specificity towards adenosine compounds, this new protein of the PFK-B family corresponds to an adenosine kinase from B. canis rossi. It was named BcrAK.


Subject(s)
Adenosine Kinase/genetics , Adenosine Kinase/metabolism , Babesia/enzymology , Babesia/genetics , Adenosine Kinase/chemistry , Amino Acid Sequence , Animals , Antigens, Protozoan/chemistry , Antigens, Protozoan/genetics , Babesia/immunology , Cloning, Molecular , DNA, Complementary/genetics , DNA, Protozoan/genetics , Escherichia coli/genetics , Humans , Molecular Sequence Data , Molecular Weight , Recombinant Fusion Proteins/chemistry , Recombinant Fusion Proteins/genetics , Recombinant Fusion Proteins/metabolism , Sequence Homology, Amino Acid
7.
J Eukaryot Microbiol ; 46(3): 298-303, 1999.
Article in English | MEDLINE | ID: mdl-10377990

ABSTRACT

The parasites Babesia canis and Babesia gibsoni (phylum Apicomplexa) are responsible for canine babesiosis throughout the world. Babesia canis was previously described as a group of three biologically different subspecies, namely B. canis canis, B. canis vogeli, and B. canis rossi. We report partial sequences of small subunit ribosomal RNA gene (ssu-rDNA) of each subspecies amplified in vitro with primers derived from a semi-conserved region of the ssu-rDNA genes in other Babesia species. The polymerase chain reaction combined with a restriction fragment length polymorphism analysis, using HinfI and TaqI restriction enzymes, confirmed the separation of B. canis into three subspecies. These sequences were compared with previously published sequences of other Babesia species. A phylogenetic approach showed that the three subspecies of B. canis belong to the clade of Babesia species sensu stricto where B. canis canis clusters with B. canis rossi whereas B. canis vogeli might form a monophyletic group with the cluster B. divergens and B. odocoilei. Our results show that the three subspecies of B. canis can readily be differentiated at the molecular level and suggest that they might be considered as true species.


Subject(s)
Babesia/classification , Babesia/genetics , Babesiosis/parasitology , Genes, rRNA , Polymorphism, Restriction Fragment Length , Animals , Cattle , Cricetinae , DNA, Protozoan/analysis , DNA, Ribosomal/genetics , Dog Diseases/parasitology , Dogs , Humans , Molecular Sequence Data , Phylogeny , Polymerase Chain Reaction/methods , Sequence Analysis, DNA
8.
Ann Trop Med Parasitol ; 92(4): 489-501, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9683900

ABSTRACT

The first demonstrated case of human babesiosis in the world was reported in Europe, in 1957. Since then, a further 28 babesial infections in man have been reported in Europe. Most (83%) of the infections were in asplenic individuals and most (76%) were with Babesia divergens, a cattle parasite. Parasitaemias varied from 1%-80% of red blood cells. The usual clinical manifestations of severe B. divergens infection were severe intravascular haemolysis with haemoglobinuria. The most efficient treatment consisted of a massive blood-exchange transfusion, followed immediately by chemotherapy with clindamycin. Hundreds of cases of human infection with Babesia spp. have been reported in the U.S.A. Most cases were infected by ticks carrying the rodent parasite B. microti, but other emerging. Babesia spp. (currently known as WA1, CA1, and MO1) are increasingly involved. Several cases were the result of blood transfusion. In terms of clinical manifestations, human infections with B. microti varied widely, from asymptomatic infection to a severe, rapidly fatal disease. Parasitaemia ranged between <1% and 85%. The splenectomized, the elderly, the immunocompromised and HIV-infected patients were predisposed to severe infection. Infection with B. microti often remained subclinical or asymptomatic and were only detected through serological surveys. The currently recommended treatment of symptomatic cases is quinine plus clindamycin. A few other cases of human babesial infection have been described in China, Egypt, Mexico, South Africa and Taiwan.


Subject(s)
Babesiosis , Animals , Anti-Bacterial Agents/therapeutic use , Babesiosis/diagnosis , Babesiosis/epidemiology , Babesiosis/therapy , Babesiosis/transmission , Bites and Stings , Clindamycin/therapeutic use , Combined Modality Therapy , Europe/epidemiology , Exchange Transfusion, Whole Blood , Humans , Ticks , United States/epidemiology , Zoonoses
9.
Parasitology ; 115 ( Pt 5): 485-93, 1997 Nov.
Article in English | MEDLINE | ID: mdl-9368899

ABSTRACT

Using surface immunofluorescence isolate-specific antigens were detected on the membrane of erythrocytes infected with Babesia parasites. In addition, the strains reacted differently with Plasmagel in that the European isolate (B.c. canis) could be purified on Plasmagel effectively, whereas infected erythrocytes of the South-African isolate (B.c. rossi) could not. Experimental infection of dogs with Babesia canis isolates from geographically different areas revealed different pathology. The European isolate obtained from France exhibited transient parasitaemia, usually below 1%, associated with low PCV values and congestion of internal organs. Clinical disease was correlated with an effect on the coagulation system, and not with peripheral parasitaemia. Infection of dogs with South-African-derived isolate induced high parasitaemia usually much higher than 1%, which required chemotherapeutic treatment. In these animals clinical disease was correlated with peripheral parasitaemia and not with parameters of the coagulation system. The results show that the etiology of disease caused by these isolates of B.c. canis and B.c. rossi is different. This might have implications for the development of vaccines against these infections.


Subject(s)
Babesiosis/parasitology , Dog Diseases/parasitology , Animals , Babesia/pathogenicity , Babesiosis/epidemiology , Blood Coagulation , Dog Diseases/epidemiology , Dogs , Erythrocyte Count , Erythrocytes/parasitology , Female , France/epidemiology , Male , Prothrombin Time , South Africa/epidemiology , Species Specificity , Thrombin Time , Travel
10.
Parasitology ; 115 ( Pt 1): 81-9, 1997 Jul.
Article in English | MEDLINE | ID: mdl-9226955

ABSTRACT

Babesia divergens was cultivated in RPMI 1640 (25 mM HEPES) supplemented with 10% human serum (RPMI-10% HS) with a high percentage of parasitized erythrocytes (PPE) (> or = 40%). Standardization of in vitro tests, purification of exoantigens, biochemical studies and the safety of the culture handler motivated the development of a serum-free defined medium. Removal of serum greatly reduced the PPE but, after a period of adaptation, the culture was continuous and the parasite was able to develop a 3% routine PPE. Addition of vitamins or reduced glutathione in basal medium (RPMI) did not improve the PPE. The supplementation of basal medium with lipidic carrier (Albumax I or bovine serum albumin-Cohn's fraction V) promoted the growth of B. divergens with high PPE (> 30%) close to those obtained in RPMI-10% HS. Neither protein nor lipid fractions alone were able to restore the growth of B. divergens. Nevertheless, the whole lipid fraction from serum or Albumax I added to delipidated albumin partially restored the growth (7% PPE), indicating that the presentation of specific lipids by a carrier is crucial for the parasite. All the data indicate that Albumax I can replace human serum offering the advantages of safety, standardization for chemosensitivity tests, and exoantigen purification.


Subject(s)
Babesia/growth & development , Animals , Babesia/cytology , Culture Media, Serum-Free , Fatty Acids , Humans , Lipids/pharmacology , Serum Albumin, Bovine/pharmacology , Vitamins/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...